New anti-thrombotic product demonstrates superior benefits
New anti-thrombotic product demonstrates superior benefits Results of major international VTE prevention phase III program show superior benefits of the pentasaccharide Org31540/SR90107A Arnhem/Oss, the Netherlands, 5 December 2000 - The results of four Phase III clinical trials show that the pentasaccharide Org31540/SR90107A provides a superior benefit over a low molecular weight heparin (comparator) in preventing deep-vein thrombosis (DVT) in major orthopedic surgery patients, with an overall relative risk reduction of 50% and a similar safety profile. These promising results of the